𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study

✍ Scribed by F. Lodato; F. Azzaroli; S. Brillanti; A. Colecchia; M. R. Tamé; M. Montagnani; R. Muratori; S. Giovanelli; V. Feletti; M. L. Bacchi Reggiani; E. Roda; G. Mazzella

Book ID
108885801
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
205 KB
Volume
12
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peginterferon alpha-2a is associated wit
Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials
✍ Tahany Awad; Kristian Thorlund; Goran Hauser; Davor Stimac; Mahasen Mabrouk; Chr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 1 views

A combination of weekly pegylated interferon (peginterferon) alpha and daily ribavirin represents the standard of care for the treatment of chronic hepatitis C according to current guidelines. It is not established which of the two licensed products (peginterferon alpha-2a or peginterferon alfa-2b)

Improved outcomes in patients with hepat
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon α-2a and ribavirin
✍ Michael W. Fried; Donald M. Jensen; Maribel Rodriguez-Torres; Lisa M. Nyberg; Ad 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB 👁 2 views

Treatment response remains suboptimal for many patients with chronic hepatitis C, particularly those with genotype 1 and high levels of viremia. The efficacy of high-dose regimens of peginterferon alfa-2a and ribavirin was compared with conventional dose regimens in patients with features predicting